MY LUNG CANCER CARE PLAN
|
|
|
- Paula Dortha Evans
- 6 years ago
- Views:
Transcription
1 MY LUNG CANCER CARE PLAN MANAGE DIAGNOSIS TRACK TREATMENTS & APPOINTMENTS MONITOR SYMPTOMS FREE TO BREATHE SUPPORT LINE (844) A FREE resource for lung cancer patients & caregivers
2 We are Free to Breathe. We are a partnership of lung cancer survivors, advocates, researchers, healthcare providers and industry leaders. We are united in the belief that every person with lung cancer deserves a cure. To learn more about lung cancer, refer to our free educational patient booklet Living with a Diagnosis of Lung Cancer. Order your free copy at freetobreathe.org LIVING WITH A DIAGNOSIS OF LUNG CANCER
3 Patient Information Name: Primary care doctor: Date diagnosed: Contact: As applicable: Medical oncologist: Radiation oncologist: Thoracic surgeon: Nurse/Patient navigator: Social worker: : Contact: Contact: Contact: Contact: Contact: Contact: medical conditions: Known allergies: DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
4 About My Lung Cancer Lung cancer type: Small cell lung cancer (SCLC) Non-small cell lung cancer (NSCLC) Adenocarcinoma Biomarker test results EGFR T790M mutation KRAS PD-L1 ALK BRAF mutation ROS1 Squamous Biomarker test results PD-L1 (fill in): Large cell (fill in) Stage: Stage: Limited stage Extensive stage IA IIIA IB IIIB IIA IV IIB Date of initial biopsy: Date of follow-up biopsy: Date of plasma test for EGFR mutations, including T790M:
5 Treatment Plan Recommended treatment: Surgery Radiation Immunotherapy Chemotherapy Targeted therapy Treatment notes: Clinical trial recommended? Yes No Potential clinical trials & notes: Contact: LEARN ABOUT LUNG CANCER TREATMENT at freetobreathe.org/lung-cancer-info
6 Surgery Date scheduled: Where to go: Type: Wedge resection Lobectomy Segmentectomy Pneumonectomy Pre-surgery instructions: Post-surgery instructions: Surgery notes:
7 Radiation Therapy Start date: Where to go: Radiation type: Purpose: End date: Location in body: Side effects to watch for: Radiation therapy notes: LEARN ABOUT LUNG CANCER TREATMENT at freetobreathe.org/lung-cancer-info
8 Chemotherapy/Targeted Therapy/Immunotherapy/ Where to go: Treatment contact: Therapy regimen: Drug: Administered: (IV or pill) Dose: Start date: Treatment schedule & details:
9 Side effects to watch for: Therapy notes: LEARN ABOUT LUNG CANCER TREATMENT at freetobreathe.org/lung-cancer-info
10 Additional and Supportive Care/Side Effect Management Treatment: Example: Treatment XYZ How administered?: Dose (if applicable): Treatment schedule: Purpose: Orally 10 mg Twice daily Anti-nausea
11 Clinical Trials Find a clinical trial at freetobreathe.org/clinical-trials Clinical trial contact: Emergency/after-hours contact: Study name & number: Where to go: Drugs involved: What is being tested? Clinical trial notes: DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
12 Additional Assistance Needed Find helpful resources at freetobreathe.org/resources Caregiver support Complementary therapy Emotional/mental health Employee rights Exercise/physical therapy Fertility consultation Financial advice/assistance Insurance assistance Nutritional counseling Pain management Respiratory health Relationship counseling Sexual health Smoking cessation : The Free to Breathe Support Line is a FREE resource for patients & caregivers. Call us Monday-Friday between 8am-4pm CDT: (844) toll-free
13 General Notes DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
14 Symptom Tracker Dates: Symptom: What was done to help: Notes: Example: April Shortness of breath Doctor prescribed inhaler Used as needed
15 Dates: Symptom: What was done to help: Notes: DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
16 Symptom Tracker Dates: Symptom: What was done to help: Notes: Example: April Shortness of breath Doctor prescribed inhaler Used as needed
17 Dates: Symptom: What was done to help: Notes: DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
18
19 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
20
21 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
22
23 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
24
25 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
26
27 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
28
29 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
30
31 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
32
33 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
34
35 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
36
37 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
38
39 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
40
41 DOWNLOAD THIS RESOURCE at freetobreathe.org/care-plan
42
43 We re always seeking ways to improve our resources for patients and families. If you have feedback on this booklet or any other patient resources from Free to Breathe, please write to or call (608) If you need support, call the Free to Breathe Support Line at (844) toll-free, Monday through Friday. It is a completely free resource for patients with lung cancer and their families. Learn more at freetobreathe.org/support. FOR ADDITIONAL PATIENT RESOURCES visit freetobreathe.org This resource provided with support from
44 we are FREE TO BREATHE Free to Breathe 1 Point Place, Suite 200 Madison, WI P (608) F (608) freetobreathe.org Free to Breathe Support Line: (844) toll free October 2017 US Last Updated 10/17
UNDERSTANDING SQUAMOUS CELL LUNG CANCER
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
TARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
Charles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
Guide to Understanding Lung Cancer
Guide to Understanding Lung Cancer Lung cancer is the second most common cancer overall for men and women in the U.S., with an estimated 222,500 new cases in 2017. However, lung cancer is the most common
Personalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
LIVING WITH A DIAGNOSIS OF LUNG CANCER
LIVING WITH A DIAGNOSIS OF LUNG CANCER We are Free to Breathe. We are a partnership of lung cancer survivors, advocates, researchers, healthcare providers and industry leaders. We are united in the belief
Lara Kujtan, MD; Abdulraheem Qasem, MD
The Treatment of Lung Cancer Between 2013-2014 at Truman Medical Center: A Retrospective Review in Fulfillment of the Requirements of Standard 4.6 (Monitoring Compliance with Evidence- Based Guidelines)
Cancer Survivorship NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN. Resources and Tools for the Multidisciplinary Team
NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN Cancer Survivorship Resources and Tools for the Multidisciplinary Team Your survivorship care plan is a summary of your tumor treatments and recommendations for
:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
Documenting the journey
Documenting the journey A lung cancр patiнt s journal LUNG CANCER INITIATIVE OF NORTH CAROLINA There is no medicine like,פho no incentive so great, and no tonic so powerful as expectation of something
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
lung adenocarcinoma What you need to know about... TYPES OF LUNG CANCER
TYPES OF LUNG CANCER What you need to know about... lung adenocarcinoma Copyright 2018 LUNGevity Foundation All rights reserved. No part of this publication may be reproduced, distributed, or transmitted
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
A Clinical Context Report
Non-small Cell Lung Cancer in Practice An Expert Commentary With Karen Reckamp, MD A Clinical Context Report Clinical Context: NSCLC in Practice Expert Commentary Jointly Sponsored by: and Clinical Context:
Case Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
Treatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference
The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com Perspectives
squamous cell lung cancer
TYPES OF LUNG CANCER UPDATED FEBRUARY 2016 What you need to know about... squamous cell lung cancer Copyright 2018 LUNGevity Foundation All rights reserved. No part of this publication may be reproduced,
Infrastructure for Clinical Data Exchange
Infrastructure for Clinical Data Exchange Amy Abernethy, MD, PhD FEBRUARY 29 2016 Instrument Data Highly Structured Administrative Data Highly Structured Clinical Research Data Intentionally Structured
Logistics of Alchemist Screening Trial A Shauna Hillman, Statistician Chelsea Schultz, Data Manager Alliance SDC
Logistics of Alchemist Screening Trial A151216 Shauna Hillman, Statistician Chelsea Schultz, Data Manager Alliance SDC Alliance Fall Meeting Nov, 2014 Presentation Objectives To Provide Background and
1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
Non-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
RADIATION THERAPY RADIATION THERAPY. In this section, you will learn about:
RADIATION THERAPY RADIATION THERAPY In this section, you will learn about: How radiation therapy works What to expect from your CT planning appointment What to expect from your treatments Your radiation
Non-Small Cell Lung Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology
Non-Small Cell Lung Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed
Lung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
LUNG CANCER TREATMENTS UPDATED MAY What you need to know about... targeted therapy
LUNG CANCER TREATMENTS UPDATED MAY 2018 What you need to know about... targeted therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people
Making a plan can help you be confident about your journey with EGFR+ lung cancer.
FOR PEOPLE LIVING WITH EGFR+ LUNG CANCER Making a plan can help you be confident about your journey with EGFR+ lung cancer. Learn more now so you can be prepared for your next steps. MAKE A PLAN TODAY
Your Medical Details and Treatment Tracker. About You
This document is intended to help you keep a record of important details that you may need to share with healthcare professionals throughout your Living with Neuroendocrine Tumours (NETs) journey. Take
Living With Lung Cancer. Patient Education Guide
Living With Lung Cancer Patient Education Guide A M E R I C A N C O L L E G E O F C H E S T P H Y S I C I A N S Your doctor has just told you that you have lung cancer. Even if you thought that you might
Traditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
SIDE EFFECTS SIDE EFFECTS. In this section, you will learn about: Managing your side effects Tracking your side effects
SIDE EFFECTS SIDE EFFECTS In this section, you will learn about: Managing your side effects Tracking your side effects 88 Managing your side effects Cancer treatments try to destroy the cancer cells in
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
Breast Cancer Survivor Treatment Summary and Plan
Breast Cancer Survivor Treatment Summary and Plan The attached Breast Cancer Survivor Treatment Summary and Plan is a form that will summarize your cancer diagnosis and treatment. It will help you plan
11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
Good Samaritan Oncology Services. Vincennes, Indiana
Good Samaritan Oncology Services Vincennes, Indiana } Classified as a Community Cancer Center by CoC >100 and < 500 newly diagnosed cases each year Provide a full range of diagnostic and treatment services.
RADIATION THERAPY RADIATION THERAPY. In this section you will learn about:
RADIATION THERAPY RADIATION THERAPY In this section you will learn about: How radiation therapy works What to expect from your CT planning appointment What to expect from your treatments Patient Review
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
Thoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
Unparalleled access to world-renowned cancer experts
Unparalleled access to world-renowned cancer experts Call Us Toll-Free at (855) 366-7700 Posted September 2016 Cancer Bridge Unparalleled access to world-renowned cancer experts Imagine hearing those three
Ask about your diabetes medicines
Ask about your diabetes medicines This guide is to help you get the best from your diabetes medicines. This guide is to enable you to get the best from your diabetes medicines. We know that many people
Adam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
A Cancer Patient s Guide to Radiation Therapy
RADIATION THERAPY A Cancer Patient s Guide to Radiation Therapy In this booklet you will learn about: What is radiation therapy The different stages in your treatment What happens during each stage Managing
immunotherapy a guide for the patient
immunotherapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2 immunotherapy... 5 Checkpoint Inhibitors... 6-9 Monoclonal Antibodies... 9 Vaccines... 10 Adoptive T-Cell
RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
Doctor office visit checklist
Doctor office visit checklist Before the visit Gather your questions Identify symptoms Check your loved one s file Call to confirm appointment Take a list of any medicines the patient is currently taking
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
2017 Annual Report CANCER CENTER
2017 Annual Report CANCER CENTER New Lung Cancer Cases-2016 Lung cancer is the leading cause of cancer deaths, among both men and women, in the United States - claiming more lives each year than colon,
IMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
An Interactive Guide to ALK+ Lymphoma. Our understanding of lung cancer has changed From one disease to many subtypes LCD
An Interactive Guide to ALK+ Anaplastic Lymphoma Kinase Non-Small Cell Lung (NSCLC) Our understanding of lung cancer has changed From one disease to many subtypes Click to get started Learning about Lung
A GUIDE TO TREATMENT WHILE TAKING RYDAPT FOR ADVANCED SM
For patients with 3 types of systemic mastocytosis (SM)* * Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL) are
Thoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
The Expanding Value of Biomarkers in NSCLC Treatment
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/closing-gaps-nsclc/the-expanding-value-of-biomarkers-in-nsclctreatment/10283/
Non-Small Cell Lung Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology
Non-Small Cell Lung Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed
NSCLC: Navigating New Therapies and Counseling Patients in Clinical Decisions. Final Outcomes Assessment September Genentech Grant ID: G-41513
NSCLC: Navigating New Therapies and Counseling Patients in Clinical Decisions Final Outcomes Assessment September 2017 Genentech Grant ID: G-41513 Program Information Overview: With the tremendous increase
PROFILING LUNG CANCER
References: (Endnotes) 1 National Cancer Institute. Dictionary of Cancer Terms. Available at: http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618. Accessed: 28 August 2016. 2 American
Chair: W. Eberhardt, DE; S. Peters, CH. 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A. 13:30-13:45 Opening and Welcome Room B
13-04-2016 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A 13:30-13:45 Opening and Welcome Room B Chair: W. Eberhardt, DE; S. Peters, CH 13:45-14:15 Heine H. Hansen Award Lecture Room B 14:30-16:00
Advancing Health Equity in Lung Cancer Outcomes
Advancing Health Equity in Lung Cancer Outcomes Edwin J Jackson Jr. DO Pulmonary and Critical Care Medicine Disclosures Funding: American Thoracic Society 2 1 Lecture Outline Cancer Disparities Smoking
Lung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
Although the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
The Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
Lung Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology
Lung Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO The American Society of Clinical Oncology (ASCO) is the world s leading professional organization
Targeted Therapies in Lung Cancer Patient Forum
Targeted Therapies in Lung Cancer Patient Forum Welcome! What to expect today Experts in EGFR, ALK, ROS1, BRAF, MET, and RET+ lung cancers will be presenting and interacting with patients and caregivers.
The Challenge of Lung Cancer
The Challenge of Lung Cancer Despite important advances in the treatment of lung cancer, it continues to account for more cancer deaths than colon, prostate, breast, and pancreas cancer combined. In 2012,
LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
A GUIDE TO STARTING TREATMENT
A GUIDE TO STARTING TREATMENT Please see accompanying and Medication Guide. full Prescribing IDHIFA (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an
None
2014 None rosemary clooney Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
Lung and Aerodigestive malignancies
Lung and Aerodigestive malignancies Nabil F Saba MD, FACP Professor, Director of the Head and Neck Oncology Program, Winship Cancer Institute Emory University COI I am a consultant for GSK, Merck, BMS,
New Frontiers in Lung Cancer Detection, Diagnosis, and Treatment John Wells, MD MS Shyam Paryani, MD MS MHA First Radiation and
New Frontiers in Lung Cancer Detection, Diagnosis, and Treatment John Wells, MD MS Shyam Paryani, MD MS MHA First Radiation and We have no financially related disclosures However, we do have two other
Immunotherapy and Lung Cancer
Immunotherapy and Lung Cancer This booklet explains how immunotherapy uses the body s own natural defenses to treat lung cancer. So far, immunotherapy is approved for non-small cell lung cancer (NSCLC)
Patient Intake Assessment Tools for Navigation
Patient Intake Assessment Tools for Navigation Review and utilize the following with new patient referrals to the Navigation program: Psychosocial Distress Screening Tool : Commission on Cancer Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide
EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide The information in this pocket guide is intended as reference material and should not replace clinical judgment or updated
Management of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
This online (electronic) survey contains twenty four simple questions. Those marked with an asterisk (*) must be answered.
1. Type of survey This is a retrospective survey that will NOT require the disclosure of any individual patient records or data only information about overall EGFR mutation testing practices and the outcomes
Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
Lung Cancer. Understanding your diagnosis cancer.ca
Lung Cancer Understanding your diagnosis 1 888 939-3333 cancer.ca Lung Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed
WELLNESS INITIATIVE NOW
WELLNESS INITIATIVE NOW To promote personal well-being, fitness and nutrition for all TDCJ employees. November 2008 Lung cancer is cancer that forms in tissues of the lung, usually in the cells lining
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
Lung Cancer Case Study
Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
Clinical utility of precision medicine in oncology
Clinical utility of precision medicine in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900
Read, Interpret, and Communicate Test Results
Read, Interpret, and Communicate Test Results Effective interpretation of epidermal growth factor receptor (EGFR) T790M mutation test results at progression will help physicians to set patient expectations
Personal Calendar Tracker
Personal Calendar Tracker The Personal Calendar Tracker was created as a companion to the Patient and Family Reference Handbook, which was developed for people living with kidney cancer and their families.
Lung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
Small cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
Understanding surgery
What does surgery for lung cancer involve? Surgery for lung cancer involves an operation, which aims to remove all the cancer from the lung. Who will carry out my operation? In the UK, we have cardio-thoracic